Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy

Area of Science:

• Biomedical Ethics
• Neurology
• Health Policy

Background:

• The US FDA approved nusinersen in December 2016 for all spinal muscular atrophy (SMA) subtypes, marking a significant advancement.
• This approval introduced novel therapeutic options for SMA patients, their families, and healthcare providers.
• However, the high cost and complex administration of nusinersen via lumbar puncture present practical and ethical challenges.

Purpose of the Study:

• To identify and discuss key ethical challenges encountered at the institutional level in the United States concerning nusinersen treatment for SMA.
• To ensure patients with SMA receive equitable benefits from treatment while being protected from harm.
• To promote fair treatment and transparency among all stakeholders involved in SMA care.

Main Methods:

• Qualitative analysis of institutional-level challenges.
• Discussion of six critical ethical considerations: cost, limited evidence, informed consent, treatment allocation, responsibility distribution, and stakeholder transparency.

Main Results:

• Identified six major institutional challenges impacting nusinersen implementation for SMA.
• These challenges include significant financial costs, insufficient long-term evidence, complexities in obtaining informed consent, and difficulties in equitable treatment allocation.
• Fair distribution of responsibilities and maintaining transparency with stakeholders were also highlighted as critical issues.

Conclusions:

• Addressing these six ethical challenges is crucial for optimizing nusinersen's benefit to SMA patients.
• Ensuring patient protection from harm and promoting fair treatment requires a comprehensive understanding of these institutional hurdles.
• Proactive strategies are needed to navigate the complexities of cost, access, and ethical considerations in SMA therapy.